In the DAPA-HF Trial [12], involving 4744 heart failure patients with a reduced ejection fraction, dapagliflozin (an SGLT-2 inhibitor) was compared to a placebo over an average of 18.2 months. The gene discussed is SLC5A2; the disease is heart failure.